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Polo-like kinase 1 (Plk1) is overexpressed in a wide spectrum of human tumors, being fre-
quently considered as an oncogene and an attractive cancer target. However, its contribution
to tumor development is unclear. Using a new inducible knock-in mouse model we report
here that Plk1 overexpression results in abnormal chromosome segregation and cytokinesis,
generating polyploid cells with reduced proliferative potential. Mechanistically, these cyto-
kinesis defects correlate with defective loading of Cep55 and ESCRT complexes to the
abscission bridge, in a Plk1 kinase-dependent manner. In vivo, Plk1 overexpression prevents
the development of Kras-induced and Her2-induced mammary gland tumors, in the presence
of increased rates of chromosome instability. In patients, Plk1 overexpression correlates with
improved survival in speciﬁc breast cancer subtypes. Therefore, despite the therapeutic
beneﬁts of inhibiting Plk1 due to its essential role in tumor cell cycles, Plk1 overexpression has
tumor-suppressive properties by perturbing mitotic progression and cytokinesis.
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Chromosomal instability (CIN) is a frequent feature both insolid and hematopoietic human tumors1,2. Although itscausal role during tumor development is still under careful
experimental scrutiny, it is now clear that CIN provides speciﬁc
clones with a variety of chromosomal combinations that may
favor either tumor growth or resistance to antitumor therapies3–5.
Multiple oncogenic alterations may induce CIN, although the
copy number aberrations that ultimately arise do so as a con-
sequence of defects in the cellular machinery that regulates
chromosome segregation and protects from unequal chromosome
inheritance during mitosis1,2. Whether alteration in the levels of
the encoded proteins is a cause or consequence of CIN is not
clear, although experimental overexpression of several compo-
nents of the CIN signature such as Mad26, cyclin B1 and cyclin
B27, as well as Aurora B8 induces CIN and spontaneous tumor
formation in mouse models9.
Plk1 is the most studied member of a conserved family of
protein kinases (Plk1–5) involved in cell division as well as spe-
ciﬁc functions in postmitotic cells such as neurons10 or smooth
muscle cells11. Plk1 was originally identiﬁed in Drosophila as a
protein involved in spindle formation and further studies have
suggested critical functions for this kinase in centrosome biology,
spindle dynamics, chromosome segregation, and cytokinesis12,13.
Genetic ablation of Plk1 or its chemical inhibition results in
defective chromosome segregation commonly accompanied by
cell cycle arrest or cell death in a variety of model organisms13,14.
Plk1 induction has been proposed to play a role at early stages
during the progression of certain carcinomas and its over-
expression inversely correlates with the survival rate of patients
with non-small cell lung, head and neck, and esophageal cancer,
among others15–17. Plk1 inhibition with speciﬁc small molecule
inhibitors is currently considered as an attractive therapeutic
strategy against speciﬁc tumor types such as leukemia and non-
small cell lung cancer18–20.
From the previous studies, Plk1 has been frequently considered
as a classical oncogene. However, the cellular effects of Plk1
overexpression in malignant transformation and their implica-
tions in tumor development have not been analyzed. In this
study, we found that Plk1 overexpression functions as a tumor
suppressor both in vitro and in vivo. Elevated levels of Plk1 delay
mammary gland tumor formation driven by classical oncogenes
such as KrasG12D or Her2. At the cellular level, these effects are
accompanied by multiple aberrations during mitosis, as well as
impaired loading of ESCRT complexes during cytokinesis because
of increased Plk1 kinase activity. Importantly, increased levels of
Plk1 in breast cancer patients is associated with better prognosis.
Results
A new mouse model for inducible Plk1 overexpression. To
investigate the consequences of Plk1 overexpression we ﬁrst
generated KH2 mouse embryonic stem (ES) cells21 in which a
FLAG-tagged human Plk1 cDNA was introduced downstream of
the ColA1 gene (Fig. 1a). In this construct, the FLAG-Plk1 cDNA
is expressed under the tetracycline-inducible operator (tetO)
sequences and it is therefore induced after the activation of the
reverse tetracycline transactivator (rtTA; expressed in the Rosa26
locus) with the tetracycline derivative doxycycline (Dox; Fig. 1a).
Treatment of these ES cells with Dox resulted in rapid induction
of FLAG-Plk1 (Fig. 1b), which was detected in the spindle poles
and the spindle during mitosis suggesting a proper localization of
the encoded FLAG-Plk1 protein (Fig. 1c). We then generated
heterozygous (referred to as ColA1(+/Plk1) or (+/Plk1) in brief)
or homozygous (Plk1/Plk1) knockin mice after microinjection of
these ES cells into developing morulas. These knockin mice also
expressed the Rosa26-rtTA (referred to as rtTA) transactivator
either in heterozygocity (+/rtTA) or homozygocity (rtTA/rtTA)
(Fig. 1a), resulting in an efﬁcient induction of FLAG-Plk1
expression in different tissues after administration of Dox (Fig. 1d
and Supplementary Fig. 1a).
We ﬁrst induced FLAG-Plk1 expression in vivo using
heterozygous or homozygous knockin mice in the presence of
two copies of the transactivator [(+/Plk1); (rtTA/rtTA) or (Plk1/
Plk1); (rtTA/rtTA), respectively]. Unexpectedly, most of these
animals died (Supplementary Fig. 1b) as a consequence of a rapid
loss of weight (Supplementary Fig. 1c) during the ﬁrst weeks on
the Dox diet and with reduced counts of red blood cells, white
blood cells, and lymphocytes (Supplementary Fig. 1d). Double
heterozygous mutants [(+/Plk1);(+/rtTA)] treated with Dox since
birth displayed a slightly reduced tumor-free survival (Fig. 1e),
accompanied by a slight but non-signiﬁcant increase in some
tumors such as lymphomas and sarcomas (Supplementary Fig. 1e,
f). Overexpression of Plk1 in Dox-treated (+/Plk1);(+/rtTA) mice
was accompanied by alteration in the nuclear size and loss of
architecture in some tissues such as bronchial epithelia, pancreas,
or liver (Fig. 1f).
Plk1 overexpression impairs proliferation and transformation
in vitro. To analyze the cellular consequences of Plk1 over-
expression during cell division, we next used (+/Plk1);(+/rtTA)
or (Plk1/Plk1);(+/rtTA) mouse embryonic ﬁbroblasts (MEFs)
generated from these mutant mice. The transgenic Plk1 was
properly located in these Dox-treated MEFs, showing cytoplasmic
and nuclear localization in interphase cells with preferential
localization to the centrosomes, as well as decorating the spindle
poles, kinetochores, and the cytokinesis midbody in mitotic cells
(Supplementary Fig. 2a, b). Induction of Plk1 at intermediate or
high levels in MEFs (Fig. 2a) resulted in defective cell prolifera-
tion (Fig. 2b–d), accompanied by the formation of higher number
of polyploid cells that accumulated with time (Fig. 2e, f) without
increasing apoptosis (Supplementary Fig. 2c). Plk1 over-
expression also induced upregulation of the tumor suppressor
p53 as well as its target p21Cip1 (Supplementary Fig. 2d) and led
to the generation of senescent cells characterized by the expres-
sion of senescence-associated β-galactosidase and ﬂat morphol-
ogy (Supplementary Fig. 2e).
We next asked whether Plk1 overexpression could cooperate
with oncogenic transformation by HrasV12 in immortal MEFs.
As depicted in Fig. 2g, Plk1 overexpression dramatically reduced
the number of Ras-transformed foci, and these transformed cells
were unable to grow in soft agar (Fig. 2h). Additionally, HrasV12
and E1A transformed primary MEFs also grow slower after Dox
administration compared to uninduced clones (Supplementary
Fig. 2f, g) and Plk1 expression continued to generate binucleated
cells (Supplementary Fig. 2h), despite being transformed. Finally,
to provide further evidence that Plk1 overexpression facilitates
polyploidization in non-transformed human cells, MCF10A-rtTA
cells were infected with a Dox inducible Plk1 vector. As shown in
Supplementary Fig. 2i, Plk1 overexpression resulted in a
signiﬁcant increase in binucleated cells after 48 h on Dox. All
together, these results suggest an antiproliferative effect of Plk1
overexpression in these assays.
We also checked whether the negative effects of Plk1
overexpression were uniquely present in p53-proﬁcient cells.
We generated MEFs derived from (+/Plk1); (rtTA/rtTA); p53
(−/−) and (Plk1/Plk1); (rtTA/rtTA); p53(−/−) mice and tested
the effect of Dox-mediated induction of Plk1. Plk1 overexpression
in p53-null cells also resulted in deﬁcient cell proliferation
(Supplementary Fig. 3a) in the presence of highly polyploid cells
(Supplementary Fig. 3b). In addition, lack of p53 did not rescue
the defects in cell transformation induced by Plk1 overexpression
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in the presence of the HrasV12 oncogene (Supplementary Fig. 3c),
suggesting that the anti-proliferative defects induced by Plk1
overexpression do not require an active p53-mediated response.
Plk1 overexpression disrupts proper chromosome segregation
and cytokinesis. Since Plk1 has been involved both in DNA
replication as well as in mitosis22,23, we ﬁrst tested whether Plk1
induction had any obvious effect in DNA replication. Treatment
with Dox did not alter the number of cells entering S-phase at
early time points in the ﬁrst cell cycle after stimulation of cell
cycle entry with serum (Supplementary Fig. 4a). In addition, we
did not observe a signiﬁcant increase of DNA damage foci (as
detected with antibodies against phosphorylated (γ)-H2AX or
53BP1) after Plk1 overexpression, suggesting no major defects in
DNA replication (Supplementary Fig. 4b, c).
We next followed progression throughout mitosis using time-
lapse microscopy in cells co-expressing GFP-tagged histone H2B.
Overexpression of Plk1 lead to a variety of mitotic defects such as
monopolar and multipolar spindles in prometaphase, as well as
ColA1 locus































































































Fig. 1 Generation of Plk1-inducible mice. a Schematic representation of the alleles used in this work. A cassette containing the human FLAG-Plk1 cDNA
downstream of the tetO sequences is inserted in the endogenous ColA1 locus after homologous recombination in KH2 ES cells. This allele [ColA1(Plk1) or
(Plk1) in short] is later combined with the Rosa26-rtTA allele expressing the tetracycline transactivator. b (+/Plk1);(+/rtTA) ES cells were treated with Dox
and FLAG and Plk1 signal was detected using speciﬁc antibodies at the indicated time points. Vinculin was used as a loading control. c Immunoﬂuorescence
of (+/Plk1);(+/rtTA) ES cells treated with Dox for 12 h. FLAG (green) is concentrated at the spindle poles with some signal in the spindle microtubules and
additional diffuse signal as expected for Plk1. α-tubulin is in red and DAPI in blue. Scale bar 5 μm. d Immunodetection of Flag-Plk1 in the indicated tissues
from (+/+);(rtTA/rtTA); (+/Plk1)(+/rtTA) and (+/Plk1)(rtTA/rtTA)mice treated with Dox for 8 weeks. Scale bar 100 μm. e Tumor-free survival of (+/+);
(+/rtTA) and (+/Plk1)(+/rtTA) mice fed with Dox since birth during 85 weeks. (+/+)(+/rtTA), 19 mice; (+/Plk1)(+/rtTA), 24 mice. p= 0.2836; Log-
rank (Mantel–Cox) test. f Sections of Dox-treated (+/+);(+/rtTA) and (+/Plk1)(+/rtTA) mice after staining with hematoxylin and eosin (H&E) or
immunodetection of Plk1 (right panel). Cells with abnormally large nuclei are indicated with arrows. Black scale bar: 100 μm, blue scale bar: 50 μm
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lagging chromosomes and anaphase bridges (Fig. 3a–e) resulting
in increased duration of mitosis (Fig. 3d). In line with these
defects, a signiﬁcant percentage of cells (26.7% vs. 1.1% in control
cells; Fig. 3a, b) exited mitosis in the absence of chromosome
segregation. In addition, 38% of Plk1-overexpressing cells
displayed abnormal cytokinesis resulting in binucleated cells or
underwent mitotic regression (7.0% of Dox-treated vs. 3.4%
untreated cells) thereby generating tetraploid cells with a single
nucleus (Fig. 3a, b). Immunoﬂuorescent analysis of these cultures
revealed increased mitotic aberrations such as lagging chromo-
somes and cytokinesis bridges (Fig. 3e). Finally, treatment of
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Fig. 2 Plk1 overexpression results in proliferative defects in cultured MEFs. a Expression of Plk1 in MEFs with the indicated genotypes, after 24 h treatment
with doxycycline. Cell lysates were immunoblotted with anti-Plk1, anti-Flag, anti-pH3, and anti-vinculin as a loading control. b Quantiﬁcation of conﬂuence
in cultures with the indicated genotypes in the absence (–Dox) or presence (+Dox) of doxycycline for 7 days. ****p < 0.0001; two-way ANOVA.
c Percentage of EdU-positive cells in (+/Plk1);(rtTA/rtTA) cultures untreated or treated with Dox for 3 days. Cells were exposed to EdU for 1 h before the
analysis. ***p < 0.001; Student’s t-test. d Percentage of mitotic cells in (+/Plk1);(rtTA/rtTA) cultures untreated or treated with Dox for 2 days as detected
by phospho-Ser10 Histone H3 immunoﬂuorescence. **p < 0.05; one-way ANOVA. e DNA content in (+/Plk1);(rtTA/rtTA) cells untreated or treated with
Dox for 1 or 2 days. The percentage of 2N, 4N, or 8N cells is indicated in the histograms. f Metaphase spreads of (+/Plk1);(rtTA/rtTA) cells untreated or
treated with Dox for the indicated time. The number of chromosomes per cell is shown in the plot (n= 25 (–Dox), n= 41 (24 h), n= 25 (48 h), n= 16 (72
h) cells per condition). ns not signiﬁcant; *p < 0.05, ***p < 0.001; one-way ANOVA. g Focus formation assays of (+/Plk1);(rtTA/rtTA) MEFs transfected
with oncogenic HrasV12 or control GFP-expressing vectors in the absence (–Dox) or presence (+Dox) of doxycycline. The number of foci is indicated in
the histogram. ****p < 0.0001 (n= 3 replicates); one-way ANOVA. h Soft agar colony formation of immortal Hras transformed MEFs. Colonies are grown
in the absence of Dox for 20 days (gray upper panels), or in the presence of Dox since plating (purple mid panels). Additionally, colonies grown in the
absence of Dox were supplemented with Dox at day 8 (lower panels). Colony diameter (in microns) is quantiﬁed in the right histogram. Each dot
represents one colony (over 50 colonies are quantiﬁed in each set). *p < 0.01; ****p < 0.0001, one-way ANOVA Bonferroni test
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number of binucleated cells (Fig. 3f), in agreement with a failure
in cytokinesis.
To determine whether elevated Plk1 levels resulted in increased
Plk1 activity at different cellular localizations, we stained Plk1-
overexpressing cells with an antibody that recognizes phosphor-
ylation on Thr210 at the Plk1 T-activation loop. Quantiﬁcation of
this signal revealed a signiﬁcant increase in Plk1-pT210 levels in
interphase cells with centrosomes separated into the two poles
(characteristic of late G2 cells; Fig. 4a). Furthermore, this signal
was also signiﬁcantly increased in prometaphase and metaphase
cells (Fig. 4b), as well as in single prometaphase kinetochores
during prometaphase in Plk1-overexpressing cells (Fig. 4c). The
centromeric levels of Sgo1, a protector of centromeric cohesion,
were reduced in Plk1-overexpressing cells (Fig. 4d) in agreement
with previous data suggesting that Plk1 activity leads to
dissociation of Sgo1 from centromeres24. In line with these
observations, a signiﬁcant number of Plk1-overexpressing cells
displayed reduced cohesion as observed in metaphase spreads
after treatment of cells with the microtubule poison colcemid
(Fig. 4e).
Plk1 overexpression impairs cell abscission. Cytokinesis failure
was among the most common phenotypes induced by Plk1
overexpression leading to 40% of binucleated cells in cultured
MEFs (Fig. 3f). Plk1 is known to modulate cell abscission by
regulating the recruitment of endosomal sorting complex
required for transport (ESCRT) machinery to the site of bridge
severing25–27. During mitosis, Plk1 phosphorylates Cep55 thereby
preventing its premature association with the midzone until
cytokinesis entry25,26. Plk1 inactivation during anaphase allows
Cep55 dephosphorylation and translocation to the midbody,
thereby resulting in the localization of ESCRT proteins to the
bridge. We therefore asked whether Plk1 overexpression could
lead to defective abscission as a consequence of deregulation of
this pathway.
A detailed analysis of cytokinesis defects in Plk1-
overexpressing cells showed a signiﬁcant number of cytokinesis
aberrations (Fig. 5a) as well as increased length of the cytokinesis
bridge in agreement with delayed abscission (Fig. 5b). During
cytokinesis, the midbody is formed by compacted bundles of
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Fig. 3 Mitotic defects in Plk1-overexpressing MEFs. a Time-lapse microscopy of Plk1 MEFs untreated (upper panel) and after 8 h on Dox (lower panels),
indicating mitotic cells; H2B-GFP (green), classiﬁed based on the three major phenotypes resulting in a tetraploid progeny in the case of Plk1
overexpression. Scale bar 20 μm. b Percentage of occurrence of each major phenotype in –Dox (n= 141) and +Dox (n= 164) MEFs. c Percentage of
mitotic errors per MEF (–Dox: 141 cells; +Dox: 164 cells); points represent individual MEF line. d Duration of mitosis in the MEF cultures (–Dox: 141 cells;
+Dox: 164 cells). In c, d, ****p < 0.0001, Student’s t-test. e Immunoﬂuorescence against α-tubulin and pericentrin in primary MEFs after 24 h on Dox
followed by quantiﬁcation of each mitotic phase and percentage of mitotic aberrancies (–Dox: n= 149 mitotic cells; +Dox: n= 166 mitotic cells). ****p <
0.0001; two-way ANOVA. Scale bar, 10 μm. f Immunoﬂuorescence against α-tubulin and γ-tubulin in (+/Plk1)(rtTA/rtTA) MEFs untreated (–Dox) or
treated with Dox for 48 h (+Dox). Binucleated cells (arrowheads) from the total population (>100 cells from at least four random microscope ﬁelds are
quantiﬁed in each replicate). ****p < 0.0001 (n= 2 replicates); one-way ANOVA. Scale bar, 10 μm
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RacGAP1 (also known as Cyk4) and MKLP1 (also known as
Kif23 or centraspindlin). RacGAP1, a Plk1 substrate involved in
RhoA activation and local actomyosin contraction28,29, was
properly activated at the midbody in Plk1-overexpressing cells
(Supplementary Fig. 5a). Similarly, loading of the midbody core
kinesin MKLP1, a plus-end directed motor protein involved in
the formation of the cleavage furrow in late anaphase and in
cytokinesis30, was not affected (Supplementary Fig. 5b), suggest-
ing no defects in the preassembled midbody in cells over-
expressing Plk1.
Abscission is ultimately mediated by binding of the adapter
protein Cep55 to MKLP1 in the preassembled midbody. During
mitosis, phosphorylation of Cep55 by Plk1 prevents its premature
loading to this structure, whereas Plk1 degradation during
anaphase results in Cep55 dephosphorylation and loading to
the midbody26. Cep55 then promotes abscission by recruiting
ESCRT-I membrane-remodeling proteins27,31,32. In agreement
with a role for Plk1 in preventing Cep55 loading, Plk1
overexpression resulted in a signiﬁcant reduction in the
localization of Cep55 to the midbody (Fig. 5c). Mislocalization
of Cep55 was accompanied by reduced loading of the ESCRT-I
component TSG101 (Fig. 5d). Importantly, direct inhibition of
Plk1 kinase activity by 1-h treatment with the Plk1 inhibitor
BI2536 signiﬁcantly rescued the midbody levels of Cep55 (Fig. 5c)
and TSG101 (Fig. 5d) in Plk1-overexpressing cells. Moreover,
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binucleation (Fig. 5e), suggesting that cytokinesis failure is a
consequence of increased kinase activity and defective midbody
loading of Cep55 and ESCRT complexes in Plk1-overexpressing
cells.
Delayed tumor progression in Plk1-overexpressing mice. To
monitor the effects of Plk1 overexpression during tumor devel-
opment in vivo, we used a mouse mammary gland tumor model
in which an oncogenic Kras (KrasG12D) allele is induced by a
tetracycline transactivator expressed under the control of the
mammary gland tumor virus (MMTV) sequences5. These mice
develop mammary gland tumors with complete penetrance and a
median latency of 23 weeks. Strikingly, Plk1 overexpression
prevented tumor development by KrasG12D in 85% of the mouse
colony and signiﬁcantly delayed tumor latency in the rest of the
colony (Fig. 6a). We reproduced these results using a second
model in which breast tumors were induced by the Her2 onco-
gene5. Similar to the previous model, Plk1 overexpression also
prevented tumor development in 45% of the colony and sig-
niﬁcantly delayed tumor onset in the remaining animals (Fig. 6b).
In addition, the number of tumors per animal was signiﬁcantly
reduced after Plk1 overexpression in these models (Fig. 6c). In
line with the polyploid phenotype observed in cultured MEFs,
overexpression of Plk1 resulted in increased nuclear volume in
tumor cells (Supplementary Fig. 6a, b). In addition, these Plk1-
overexpressing tumor cells displayed a higher frequency of
aneuploidy and polyploidy compared to the single oncogene
tumors (Fig. 6d–f). To analyze if high Plk1 levels inﬂuence
chromosome instability during tumor growth, we performed time
lapse microscopy of tumor cells. Indeed, 50% of Her2/Plk1 tumor
cells displayed mitotic errors compared to 24% of Her2 alone. In
addition, 25% of Her2/Plk1 tumor cells became polyploid while
this only occurred in 3% of Her2 tumor cells (Fig. 6g, h). A
common consequence of polyploidy is the activation of p21
through a p53-dependent mechanism resulting in cell cycle arrest.
In agreement with our previous data in Plk1-overexpressing
MEFs, we also observed a signiﬁcant increase of p21-positive cells
in Plk1-expressing tumors, compared to oncogene alone (Sup-
plementary Fig. 6c, d). Moreover, the percentage of cells pro-
liferating in these tumors was signiﬁcantly lower than in Kras or
Her2 tumors alone (Supplementary Fig. 6c, d), suggesting that in
mammary tumors Plk1 overexpression results in increased CIN
and growth inhibition.
To identify early effects of Plk1 overexpression in vivo, we
surgically removed mammary glands from the KrasG12D; Plk1
model 4 days and 100 days after induction of the transgenes
(Supplementary Fig. 7a, b). Immunostaining with a Plk1 antibody
as well as RT-PCR conﬁrmed the expression of both Kras and
Plk1 transgenes (Supplementary Fig. 7a, b). KrasG12D and Plk1-
overexpressing models displayed increased number of phospho-
histone H3-positive cells suggesting either increased cell pro-
liferation or increased duration of mitosis (Supplementary
Fig. 7c). However, Plk1-overexpressing tissues were characterized
by the presence of cells with higher nuclear volume (Supplemen-
tary Fig. 7d) as well as increased apoptotic cell death with
independence of Kras status (Supplementary Fig. 7e) at these
early time points, likely contributing to reduced tumor burden in
the presence of elevated Plk1 levels.
To monitor single-cell fate of epithelial cells in vivo after Plk1
overexpression, we used a three-dimensional culture system of
primary mammary epithelial cells5,33 isolated from these mouse
models. Single cells were embedded in matrigel and allowed to
develop acinar structures for 6–8 days. Once spheres were
formed, we induced transgene expression with Dox and followed
cell division of these cells co-expressing GFP-tagged histone H2B
using time-lapse microscopy. In line with previous results5,
control and KrasG12D-induced cultures had no obvious pheno-
type after 36 h on Dox (Fig. 7a) and the mitosis observed were
normal. However, similar to the observations in cultured MEFs,
overexpression of Plk1 in mammary epithelial cells resulted in a
signiﬁcant prolonged mitosis (Fig. 7a, b) in the presence of
abnormal mitotic ﬁgures, including lagging chromosomes,
defective chromosome segregation, and cytokinesis failure (Fig. 7c,
d). All together, these data suggest that Plk1 overexpression
results in defective mitosis and cytokinesis in mammary gland
epithelial cells, thus suppressing tumor development.
Plk1 expression correlates with genome-doubled breast can-
cers. Next, to explore the relationship between PLK1 expression
and ploidy in human breast cancers, we obtained matched copy
number and expression data for 953 breast tumors from the
TCGA. Consistent with an association between PLK1 expression
and polyploidy, we observed a highly signiﬁcant difference in
levels of PLK1 expression in tumors which exhibited evidence of
having undergone a genome doubling event during their evolu-
tion compared to their non-doubled counterparts (Fig. 8a, p=
4.62e-09, t-test). Furthermore, the association between genome
doubling and PLK1 expression levels remained signiﬁcant in
TP53 wild-type tumors, suggesting that PLK1 may facilitate
polyploidization in a TP53-independent manner (Fig. 8b, p=
3.37e-06, t-test).
Finally, to investigate the clinical signiﬁcance of PLK1
expression in breast cancer, we grouped tumors into those with
low PLK1 expression (bottom quartile PLK1 expression) and
Fig. 4 Plk1 overexpression induces defects in centrosome and chromosome segregation dynamics. a Immunoﬂuorescence against p-Plk1-T210 and
pericentrin in MEFs untreated or after 24 h with doxycycline (+Dox). The histogram shows the quantiﬁcation of mean ﬂuorescence intensity (MFI) of p-
Plk1-T210 staining at the centrosomes during late G2 phase (separated; –Dox: n= 54 centrosomes; +Dox: n= 34 centrosomes) or earlier interphase (joint;
–Dox: n= 88 centrosomes; +Dox: n= 58 centrosomes; n= 2 replicates). Scale bar, 10 μm. b Immunoﬂuorescence against p-Plk1-T210 and pericentrin in
MEFs untreated or after 24 h on Dox. The histogram shows the quantiﬁcation of mean ﬂuorescence intensity (MFI) of p-Plk1-T210 staining at each mitotic
phase [Prometaphase (PM): –Dox n= 22 cells; +Dox: n= 26 cells; Metaphase (M): –Dox n= 17 cells; +Dox: n= 21 cells; Anaphase (A): –Dox n= 15 cells;
+Dox: n= 12 cells; Cytokinesis (C): –Dox n= 13 cells; +Dox: n= 15 cells; n= 3 replicates]. c Immunoﬂuorescence against p-Plk1-T210 in primary MEFs
untreated or after 24 h on Dox. The histogram shows the quantiﬁcation of mean ﬂuorescence intensity (MFI) of p-Plk1-T210 staining at individual
kinetochores of cells in prometaphase (–Dox: n= 51 kinetochores; +Dox: n= 51 kinetochores; n= 2 replicates) **p < 0.01; Mann–Whitney test. Scale bar,
10 μm. d Immunoﬂuorescence against Sgo1 in primary MEFs untreated or after 24 and 72 h on Dox. The ﬁrst histogram shows the quantiﬁcation of mean
ﬂuorescence intensity (MFI) of Sgo1 staining in the entire cell at prometaphase (–Dox n= 33 cells; +Dox 24 h: n= 35 cells; +Dox 72 h: n= 52 cells; n= 3
replicates). The second histogram shows the percentage of prometaphase cells with diffused Sgo1 staining (n= 3 replicates). Scale bar, 10 μm. In a, b, d, n.
s. not signiﬁcant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; one-way ANOVA. e Chromosome spreads (DAPI stained) from (+/Plk1);(rtTA/rtTA)
MEFs untreated or treated with Dox at the indicated times. Chromosome cohesion was classiﬁed in three different status: “parallel arms” as readout of full
chromatid cohesion (dark blue box), “separated arms” as readout of chromatid arm separation (mid blue), and “separated sisters” as readout of fully
separated chromatids (light blue). (–Dox, n= 24; +Dox 24 h, n= 40; +Dox 48 h, n= 25; +Dox 72 h, n= 22 cells). Scale bars, 20 μm
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Fig. 5 Overexpression of Plk1 impairs Cep55 and ESCRT loading into the cytokinesis midbody. a (+/Plk1);(rtTA/rtTA) MEFs were untreated (–Dox) or
treated for 24 h with doxycycline (+Dox), ﬁxed and stained for α-tubulin (red) and DAPI (DNA, green). Cells in cytokinesis (n > 100 per condition; n= 3
replicates) were evaluated for aberrant cytokinesis, considering the midbody formation and shape, and correct distribution of DNA into the two daughter
cells. Scale bars, 10 μm. b The length of the cytokinesis bridge was evaluated by measuring the distance in between the two daughter nuclei in MEFs
untreated or after 24 h of Dox treatment (–Dox, n= 17 cells; +Dox, 23 cells). Scale bars, 10 μm. In a, b *, p < 0.05; Student’s t-test. c MEFs expressing a
CEP55-EGFP fusion (green) were treated for 24 h with Dox (+Dox), in the absence or presence of 1 μM of the Plk1 inhibitor BI2536 for 1 h at the end of the
Dox time (Dox+ BI), or left untreated as control (–Dox). α-tubulin is in red. Data represent the percentage of cells with positive CEP55-EGFP signal at the
midbody (–Dox, n= 134; +Dox, n= 94; Dox+ BI, n= 47 cells; n= 3 replicates (–Dox, +Dox) or 2 replicates (Dox+BI)). Scale bar, 5 μm. d MEFs
expressing a Tsg101-mCherry fusion (red) were treated for 24 h with Dox (+Dox), in the absence or presence of 1 μM of BI2536 for 1 h at the end of the
Dox time (Dox+ BI), or left untreated as control (–Dox). α-tubulin is in green. Data represent Tsg101-mCherry mean intensity at the midbody (–Dox, n=
81; +Dox, n= 60; Dox+ BI, n= 37 cells; n= 2 replicates). Scale bars, 5 μm. eMEFs were treated for 24 h with Dox (+Dox), in the absence or presence of
1 μM of BI2536 for 1 h at the end of the Dox time (Dox+ BI), or left untreated (–Dox). Cells were stained for α-tubulin (red) and DAPI (DNA, green) and
binucleation index was quantiﬁed from more than 600 cells in each sample (n= 5 replicates). Scale bars, 50 μm. In c–e, n.s. not signiﬁcant; *p < 0.05; **p <
0.01; ***p < 0.001; ****p < 0.0001; one-way ANOVA
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those with higher PLK1 expression (remaining quartiles). In
keeping with the observed tumor suppressor properties of PLK1,
patients with low PLK1 expression were associated with
signiﬁcantly shorter overall survival, compared to those with
higher PLK1 expression levels (Fig. 8c, p= 0.0099; hazard ratio
(HR), 0.59; 95% conﬁdence interval (CI), 0.40–0.89). These
results remained signiﬁcant in multivariate analysis, including
PAM50 subtypes, genome doubling and TP53 status in the model
(p= 0.00144, HR= 0.51, CI= 0.33–0.77).
Discussion
Plk1 belongs to a family of kinases with multiple roles in pro-
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Fig. 6 Plk1 overexpression reduces tumor development induced by Kras or Her2 oncogenes. a Percentage of tumor-free mice after doxycycline
administration (control, n= 33; Plk1/MMTV-rtTA n= 35; KrasG12D n= 87; KrasG12D/Plk1 n= 40 mice). b Percentage of tumor-free survival after doxycycline
administration (control, n= 33; Her2, n= 51; Her2/Plk1, n= 36 mice). In a, b, ****p < 0.0001, Mantel–Cox test. c Number of tumors per animal in the
indicated genotypes; **p < 0.01; ****p < 0.0001; Mann–Whitney test. d Interphase-Fluorescent in situ hybridization (I-FISH) on parafﬁn sections of
mammary tumors using two centromeric probes against chromosomes 16 and 17. e Quantiﬁcation of the frequency of aneuploidy (left) in samples from the
indicated genotypes (control, n= 4; Kras, n= 4; Kras/Plk1, n= 3; Her2, n= 4; Her2/Plk1, n= 4 mice). *p < 0.05; ***p < 0.001; one-way ANOVA.
f Percentage of cells with 2, 3, or 4 or more chromosomes in the indicated genotypes. g Representative micrographs of Her2 and Her2/Plk1 tumor cells
in vitro (H2B-GFP green). Top: mitotic cell with a lagging chromosome. Bottom: cytokinesis failure resulting in binucleation. h Percentage of cells in Her2
tumors (H) and Her2/Plk1 (HP) with the indicated mitotic errors
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Fig. 7 Mitotic aberrations in cultured Plk1-overexpressing mammary organoids. a Time-lapse microscopy of Plk1/MMTV-rtTA mammary organoids
expressing H2B-GFP either untreated (upper panel) or after 24 h on Dox (lower panel). Yellow circles indicate mitotic cells; H2B-GFP (green). Scale bar, 18
μm. b Duration of mitosis in the organoid cultures (–Dox, 57 cells; +Dox, 43 cells). c Percentage of mitotic errors per mouse (–Dox, 57 cells from 5 mice;
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Fig. 8 Plk1 expression in human breast cancers. a Plk1 expression relative to TBP (log2) in genome-doubled (GD) and non-genome-doubled (nGD) breast
cancers from the TCGA. p= 4.62e-09, t-test. b Plk1 expression in breast cancers with and without TP53 mutations. The association between GD and Plk1
expression is signiﬁcant in TP53 wt tumors. p= 3.37e-06, t-test. c Survival analysis of breast cancer (BRCA) patients with low Plk1 expression (bottom
quartile) and those with higher Plk1 expression (remaining quartile) p= 0.0099; hazard ratio (HR), 0.59; 95% conﬁdence interval (CI), 0.40–0.89
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kinases, Plk1 is considered an interesting target for cancer therapy
due to the requirements for its kinase activity during cell division
in tumor cells13,20. However, to what extent Plk1 expression is a
cause or a consequence of carcinogenesis is under debate34. Plk1
expression is cell cycle-dependent and Plk1 is frequently over-
expressed together with other mitotic genes in highly proliferating
and chromosomally unstable tumors35. Plk1 is repressed by the
tumor suppressor p5336 and increased Plk1 levels can simply
reﬂect p53 inactivation in cancer cells37.
Although Plk1 is frequently classiﬁed as an oncogenic protein,
its contribution to malignant transformation is arguable. In pio-
neer assays in the 90’s, ectopic expression of Plk was shown to
increase DNA synthesis and mitosis in quiescent NIH 3T3 cells
and to induce oncogenic foci38. Although the molecular basis for
these observations is unknown, Plk1 can inhibit p5339 and leads
to the stabilization of Myc proteins40, suggesting possible
mechanisms for proliferative functions. However, its sufﬁciency
in triggering cell cycle entry and progression is unclear and more
recent data suggest that Plk1 overexpression leads to cell pro-
liferation defects at least partially due to aberrant mitosis and the
activation of the spindle assembly checkpoint41. Interestingly,
there are early reports showing that other Polo like family
members might also play as tumor suppressors such as Plk3 or
Plk510,42. Recent data also suggests that constitutive over-
expression of Plk1 in mice does not lead to tumor formation43,
although the mechanism has not been investigated. In our hands,
overexpression of Plk1 using an inducible knockin model in
murine cells results in decreased cell proliferation accompanied
by multiple mitotic aberrations, including defects in chromosome
congression and segregation, and abnormal cytokinesis (Figs. 2–
5). Plk1 overexpression also prevents malignant transformation of
primary cells by Ras oncogenes (Fig. 2) and impairs breast cancer
development induced by Kras or Her2 oncogenes (Fig. 6).
The pleiotropic defects caused by Plk1 overexpression are likely
a consequence of the multiple roles of this protein in several
cellular structures such as the centrosomes, kinetochores, or the
cytokinesis bridge12,13,22. Among these defects, failure in cyto-
kinesis and abscission is the most abundant defect in Plk1-
overexpressing cells, resulting in the formation of binucleated
cells as well as tetraploid mononucleated cells generated after
mitotic regression in the absence of abscission (Fig. 3). Lack of
abscission in these cells correlates with defective loading of
Cep55, a Plk1 substrate that recruits the ESCRT component
TSG101 to the cytokinesis bridge26. In the presence of high Plk1
activity, loading of the ESCRT complex into the cytokinesis
bridge is deﬁcient (Fig. 5), likely as a consequence of impaired
loading of Cep55 during late stages of anaphase. In fact, treatment
of Plk1-overexpressing cells with the Plk1 inhibitor BI2536 par-
tially rescued these defects, suggesting that cytokinesis defects in
Plk1-overexpressing cells are kinase-dependent and at least par-
tially mediated by the Cep55-ESCRT pathway. Since Plk1 is also
involved in cell migration and metastasis44, authophagy45, pen-
tose phosphate metabolism46 or blood pressure regulation11,
overexpression of this kinase in cancer cells may result in a
variety of additional abnormalities that will deserve future
analysis.
Accumulative evidences in the last decade suggest that either
downregulation or upregulation of several mitotic regulators
induce genomic instability. As a pioneering example, both the
downregulation47 and overexpression6 of Mad2 result in CIN
accompanied by the formation of chromosomally unstable
tumors in vivo. Other examples in which overexpression of a
mitotic regulator is accompanied of CIN and tumor formation
include Aurora A48,49, Aurora B8, and Cyclin B1 and Cyclin B27,
among others2,9. Contrary to these examples, Plk1 overexpression
results in a signiﬁcant delay and decreased breast cancer
incidence in combination with Kras and Her2 oncogenes. These
results are in agreement with previous observations suggesting a
tumor suppressor role for Plk1. For instance, Plk1(+/−) mice
display increased susceptibility to spontaneous tumor develop-
ment50. Although Plk1 mutations are not frequent in human
cancer cells, the only mutations found in a few cancer cell lines
generate Plk1 isoforms with decreased protein stability and
reduced protein levels51. In human breast cancer cells, Plk1
mediates estrogen receptor (ER)-regulated gene transcription
participating in the expression of genes involved in develop-
mental and tumor-suppressive functions52. Finally, contrary to
other studies, reduced levels of PLK1 have been correlated to
aggressiveness, decreased response to chemotherapy, and poor
prognosis for disease-free survival in colorectal cancer53. Simi-
larly, PLK1 protein levels correlate with better prognosis in p53
wild-type breast tumors54. A meta-analysis of breast cancer
patients suggests that PLK1 overexpression at the mRNA level
correlates with poor prognosis in ER+. However, PLK1 over-
expression correlates with better prognosis in ER-negative and
Her2-positive patients (Supplementary Fig. 8). Our analysis of
human breast cancer datasets shows that tumors with higher
PLK1 expression generally have improved prognosis (Fig. 8). All
together, these data indicate that, despite being generally con-
sidered as an oncogene, PLK1 may have tumor-suppressive
activities.
The fact that Plk1 may function as a tumor suppressor instead
of an oncogene does not necessarily argue against the use of Plk1
inhibitors in cancer therapy. Many essential components of cell
proliferation may be used as cancer targets despite having no
oncogenic activity, owed to non-oncogene addiction of cancer
cells for speciﬁc cellular processes such as cell division. Plk1 is a
frequent hit in chemical or genome-wide genetic screens to
uncover new targets under different oncogenic backgrounds55–64.
In fact, Plk1 inhibition may be particularly effective in Ras-
induced55,65 or Her2-induced66 tumors indicating that, inde-
pendently of a possible tumor suppressor role of overexpressed
Plk1, efﬁcient kinase inhibition of this protein may impair tumor
cell proliferation and survival. Plk1 inhibitors are currently being
tested in multiple solid and hematopoietic tumors and BI6727
(volasertib), a derivative of BI2536, has recently received the FDA
Breakthrough Therapy designation for its effect in acute myeloid
leukemia20,67. Understanding the speciﬁc requirements for Plk1
as compared to other essential cell cycle kinases will likely con-
tribute to a better design of therapeutic strategies against its
kinase activity.
Methods
Mouse models. KH2 ES cells, kindly provided by Konrad Hochedlinger and
Rudolf Jaenisch21, carried the M2-rtTA gene inserted within the Rosa26 allele. A
cassette containing the FLAG-human Plk1 cDNA under the control of the Dox-
responsive promoter (tetO) was inserted downstream of the Col1A1 locus (Fig. 1a).
ColA1-Plk1 heterozygous animals were bred to MMTV-rtTA, TetO-KrasG12D,
TetO-rat-Her2, and H2B-GFP5. Only heterozygous female animals for all trans-
genes were used in this study. Breeding and experimentation was performed at the
CNIO, EMBL-Monterotondo, and DKFZ animal facilities, with ethical approval
from the corresponding Animal Welfare and Ethical Review Bodies and national
and European legislations.
Mice with different combinations of the Plk1;rtTA alleles [(+/+)(rtTA/rtTA);
(+/Plk1)(+/rtTA); (+/Plk1)(rtTA/rtTA); (Plk1/Plk1)(rtTA/rtTA)] were fed with
2000 ppm Dox impregnated food in order to achieve ubiquitous transgene
expression and evaluate Plk1 expression tolerance. In all other in vivo experiments
mice were fed with 625 ppm Dox-enriched diet to exclusively express the
transgenes in the mammary gland.
Quantitative analysis of blood cell populations was performed in mice after
5 days of 2000 ppm Dox food administration. Blood was retrieved in tubes
supplemented with K3-EDTA 3 K as an anticoagulant (Aquisel; 1501126) and the
analysis was performed with a Procount veterinary hematology analyzer (serial
number 901235).
Isolation of tail-DNA was performed via incubation in 200 µL 0.05 M NaOH at
98 °C for 1.5 h and subsequent neutralization with 20 µL 1M Tris HCl pH 7.5.
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TetO-Kras, TetO-Her2, and MMTV-rtTA transgenic mice were genotyped as
described previously5. The following oligonucleotides were used to genotype the
ColA1-Plk1 allele: KH2-Plk1 A: 5′-GCACAGCATTGCGGACATGC-3′, KH2-Plk1
B: 5′-CCCTCCATGTGTGACCAAGG-3′, KH2-Plk1 C: 5′-
GCAGAAGCGCGGCCGTCTGG-3′. For all transgenes, the following PCR
program was applied: 94 °C for 2 min, 30 times [95 °C for 30 s, 60 °C for 30 s, 72 °C
for 30 s], and a ﬁnal step at 72 °C for 1 min.
Immunodetection in tissue sections. Immunohistochemistry and immuno-
ﬂuorescence in mouse tissues was performed using formalin-ﬁxed parafﬁn-
embedded sections. Following deparafﬁnization with xylene and rehydration with
graded ethanol, antigen retrieval was performed using 0.09% (v/v) unmasking
solution (Vector Labs) for 30 min in a steamer. Inactivation of endogenous per-
oxidases was carried out using 3% Hydrogen Peroxide (Sigma) for 10 min. Sec-
ondary antibody staining and biotin-streptavidin incubation were performed using
species-speciﬁc VECTASTAIN Elite ABC kits (Vector Labs). DAB Peroxidase
Substrate kit (Vector Labs) was utilized for antibody detection. Eosin Y and hae-
matoxylin were from Bio-Optica and Vector Labs. Primary antibodies used were
anti-pH3 Ser10 (1:200, Cell Signaling, 9701), FLAG (1:200, Sigma), Plk1 (1:20)68,
p21 (1:50, SC-6246), and PCNA (1:8000, AB18197). 10% goat serum (Jackson
Immuno) and species-speciﬁc Alexa ﬂuorophore-labeled goat IgG (1:800, Invi-
trogen) were used as secondary antibodies. TUNEL (In Situ Cell Death Detection
Kit, TMR red, Roche, #12156792910) was used for detecting cell death. Analysis of
images was performed using Fiji (https://ﬁji.sc/). Tumor sections were visualized
under a TissueFAXS slide scanning platform (TissueGnostics, Vienna, Austria).
For the PCNA, p21, and nuclear size analysis, the quantitation was performed
using StrataQuest software (TissueGnostics) to determine the percentage of PCNA
+, p21+ cells, and/or nuclear area.
Interphase-FISH was performed on formalin-ﬁxed parafﬁn-embedded 5-µm
sections. Following deparafﬁnization with xylene and rehydration with graded
ethanol, Vysis Parafﬁn Pretreatment IV and Post-Hybridization Wash buffer kit
was used as speciﬁed by the manufacturer. Probe mix was prepared with 3 µL of
labeled probe and 7 µL Vysis LSI/WCP Hybridization buffer. Hybridization was
performed using Abbott Molecular Thermobrite system with the following
program: Denaturation 76 °C for 5 min, hybridization at 37 °C for 20–24 h. Pan-
centromeric probes were made using pairs of BAC clones for each chromosome.
Chr 16-RP23–290E4 and RP23–356A24 labeled with SpectrumOrange-dUTP
(Vysis), and Chr 17-RP23–354J18 and RP23–202G20 labeled with SpectrumGreen-
dUTP (Vysis); the BAC DNAs were labeled by nick translation according to
standard procedures. Signal for hybridization for each probe was checked in a
minimum of 60 interphase cells as reported previously6.
Cell culture and immunoﬂuorescence. MEFs were prepared from E13.5 embryos
using standard procedures6. Primary MEFs were immortalized by using the T121
construct that encodes the ﬁrst 121 amino acids of the SV40 large T antigen. MEFs
growth curves were done by measuring cell culture conﬂuence (JuLI™ FL,
Nanoentek), each 24 h after doxycycline addition. Doxycycline concentration in all
culture experiments was 1 μg/ml. Cell cycle proﬁling analysis was performed by
counterstaining DNA with 4,6 diaminophenylindole (DAPI) and using the FACS-
Canto ﬂow cytometry device (BD Biosciences). Apoptosis was determined by
Annexin V-FITC staining (BD PharmingenTM) using the FACS-Canto ﬂow
cytometry device (BD Biosciences). For MEF proliferation analysis, EdU was added
to exponential growing MEFs for 1 h, and then cells were tripsinized and ﬁxed in
cold 70% ethanol. EdU staining protocol was done following manufacture
instructions (Click-iT, Invitrogen), and DNA was stained with DAPI for 30 min.
Entry in S-phase was quantiﬁed by synchronizing MEFs in G0 by conﬂuency and
serum starvation (FBS 0.1%) during 48–72 h. Then, MEFs were split and seeded in
10% FBS. S-phase entry was analyzed by EdU incorporation at different time points
after cell seeding (up to 32 h). Mitotic index was determined by immunostaining
with anti-histone H3-phosphoSer10 (1:500, Millipore 06–570). Cell senescence was
measured by the senescence-associated beta-gal staining kit (Cell Signaling).
Replicative stress was monitored by cell immunostaining on μCLEAR bottom
96-well plates (Greiner Bio-One), with antibodies against γ-H2aX (1:1000,
Millipore 05–636) and 53BP1 (1:1000, Novus Biologicals NB100–304). DNA was
counterstained with DAPI. Images were acquired and quantify by an Opera High-
Content Screening System (PerkinElmer). A 20× magniﬁcation lens was used and
pictures were taken at non-saturating conditions.
For chromosome cohesion analysis, MEFs were arrested in 0.1 μg/ml colcemid
(Karyomax; Thermo Fisher) for 4–6 h, harvested by trypsinization, swollen in 75
mM KCl for 30 min at 37 °C and ﬁxed in methanol:acetic acid 3:1. Fixed cells were
then dropped onto slides to obtain chromosome spreads that were stained and
mounted with DAPI. Images were taken under a Leica DM6000 microscope.
H-Ras transformation in MEFs was achieved by transfecting immortal MEFs
with HRas-V12 or a combination of HRas-V12 and E1A in primary MEFs. Cells
were then allowed to grow until contact inhibition, and then maintained in culture
for at least 3 weeks with fresh media changes every 48 h. For focus assays,
doxycycline was added to the cells once they reached conﬂuency, and before
transformed foci were present. After 3 weeks, cell transformation colonies were
either stained with Giemsa and number of colonies quantiﬁed using ImageJ
software or individual colonies grown in the absence of Dox were expanded for
further experiments. For anchorage-independent growth analysis, HRas-
transformed MEF colonies with different Plk1;rtTA genotypes were seeded in soft
agar media using routine procedures.
DNA transfection in MEFs was done using the Lipofectamine 3000 kit
(Invitrogen). MEFs were transfected either with cDNA encoding for MKLP1 fused
to GFP (Addgene #70145), CEP55 (obtained from the Mammalian Gene
Collection) fused to GFP, or the ESCRT-I member TSG101 fused to the mCherry
reporter (Addgene #38318). 48 h after transfection, the expression of each cDNA
was evaluated by immunoﬂuorescence. Time-lapse imaging was performed for 12 h
using a Leica SP5 Confocal microscope: 2 μm optical sectioning across 12 μm stack,
every 5 min.
For immunoﬂuorescence in MEFs, cells were cultured on 20-mm coverslips and
ﬁxed with 4% PFA. Blocking was done using 10% goat serum or donkey serum
(Jackson Immuno) in PBS with 0.15% Triton X. Secondary antibodies were Alexa
ﬂuorophore-labeled goat/donkey IgG (1:250, Invitrogen). We used primary
antibodies against: FLAG (1:500, Sigma F7425), Plk1 (1:2)68, Plk1-phospho-T210
(1:200, Abcam ab39068), Pericentrin (1:3000, Abcam ab4448), γ-Tubulin (1:1000,
Sigma T6557), Aurora B-phospho-T232 (1:500, Rockland 600–401–677),
RacGAP1-phospho-Ser170 (1:200, Active Motif 39265-66), Sgo1 (1:100, S. Taylor,
University of Manchester, UK), α-tubulin (1:500, Sigma T6199), and α-tubulin-
FITC conjugate (1:500, Sigma F2168). Analysis of images was performed using Fiji.
For the quantiﬁcation of mean ﬂuorescence intensity, all images were converted to
8-bit grayscale following which cell borders were traced using the free hand tool in
Fiji and mean pixel intensity for corresponding channel was calculated within the
deﬁned area.
Tumor cell culture. Mammary tumors were digested with the Mouse Tumor
Dissociation Kit (130-096-730, Miltenyi) in a gentleMACS Dissociator (130-095-
937, Miltenyi) following manufacturer’s instructions. Cells were cultured on 8-well
chambered coverglass (Thermo Scientiﬁc, 155411) in DMEM supplemented with
10% tet-Free Serum, 4mM L-glutamine (GIBCO), 100 μg/ml Penicillin/Strepto-
mycin (GIBCO), 5 µg/ml insulin (Sigma), 10 µg/ml EGF (Sigma), 1 µg/ml hydro-
cortisone (Sigma), 1 µM progesterone (Sigma), 5 µg/ml prolactin (NIHPP), and 1
μg/ml doxycycline. Time-lapse imaging during 15 h was performed on a Zeiss Cell
Observer with 2 μm optical sectioning across 18 μm stack, 30 frames/h. Zeiss Zen
2 software served for image analysis.
Human cell line culture. MCF10A (a kind gift from Prof. Brummer) were
maintained in DMEM/F12 (LONZA) supplemented with 5% bovine serum
(Invitrogen), 1% Penicillin-Streptomycin (Life Technologies), 500 ng/ml hydro-
cortisone (Sigma-Aldrich), 100 ng/ml cholera toxin (Sigma-Aldrich), 10 μg/ml
insulin (Sigma-Aldrich), and 20 ng/ml epidermal growth factor (EGF, Sigma-
Aldrich). To generate PLK1 inducible cell line, MCF10A were ﬁrst infected with an
rtTA-expressing retrovirus and selected with puromycin (1 µg/ml), and then
infected with an inducible Tet-ON lentivirus carrying the human Plk1cDNA cDNA
(pLenti CMVtight Hygro DEST from Addgene #26433) and selected with hygro-
mycin (350 µg/ml). Immunoﬂuorescence and quantiﬁcation of binucleation was
performed as described with MEFs.
RNA and protein work. For RNA analysis, snap frozen tissue was homogenized
using mortar and pestle while maintaining temperature at –80 °C using dry ice.
RNA extraction was carried out following manufacturer’s recommendations
(RNeasy Mini Kit, Qiagen). QuantiTect Reverse Transcription Kit (Qiagen) was
used for cDNA synthesis utilizing 400 ng of RNA. Quantiﬁcation using real-time
PCR was initiated using 12 ng of cDNA with SYBR Green PCR Master Mix (2×)
(Applied Biosystems) in a LightCycler II® 480 (Roche). The oligonucleotides for
Plk1 ampliﬁcation were: F-(5′-3′) AACACGCCTCATCCTCTACAAT and R: (5′-
3′) AGGAGGGTGATCTTCTTCATCA. Primers used for monitoring Kras
expression are listed in ref. 5.
For protein extraction and immunoblot, mouse tissues and MEFs were lysed in
Laemmli lysis buffer (0.25 M Tris-HCl pH 6.8, 2.5% glycerol, 1% SDS, and 50 mM
DTT). Samples were then boiled for 10 min and cleared by centrifugation. Proteins
were separated on XT Criterion Tris-Glycine acrylamide gels (BioRad), transferred
to nitrocellulose membranes (BioRad), and probed using the following speciﬁc
antibodies: anti-FLAG (1:500, Sigma F7425); anti-Plk1 (1:500, Millipore Thermo
Fisher 33–1700); anti-p53 (1:200, Cell Signaling 2524); anti-p21 (1:100, Santa Cruz
sc-397); anti-phospho Ser10 H3 (1:1000, Cell Signaling 9701); anti-α-Tubulin
(1:10,000, Sigma T9026); or anti-vinculin (1:10,000, Sigma V9131). Signal detection
was done using secondary antibodies coupled to Alexa 680 dye (1:2000, Invitrogen)
and using the Odyssey Infrared Imaging System (Li-Cor Biosciences). All original
and full size western blots are shown in Supplementary Fig. 9.
Three-dimensional organotypic assays. Mammary glands were harvested from
8–9-week-old virgin female mice and three-dimensional organoid cultures were
prepared according to published records33. Time-lapse imaging was performed
during 20 h on an inverted spinning disk confocal (Perkin Elmer Ultraview-Vox):
0.3 μm optical sectioning across 35 μm stack, 5 frames/h and for 12 h using a Leica
SP8 Confocal microscope with a resonant scanner: 0.9 μm optical sectioning across
35 μm stack, 12 frames/h.
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Human breast cancer data. TCGA RNA-Seq expression data and clinical data
were obtained from the TCGA data portal. Copy number and mutation data were
obtained from ref. 69. PLK1 expression was normalized relative to TBP and log2
transformed. Genome doubling was estimated as previously described70. Survival
analysis was performed using Kaplan–Meier curves and Cox proportional hazard
models.
Statistical analysis. GraphPad Prism 6 was utilized for all statistical testing.
Control samples for in vivo mammary gland-related experiments were obtained
from animals containing the transgenes but kept on a normal diet or animals
lacking MMTV-rtTA but placed under a doxycycline-enriched diet (625 ppm;
Harland). Non-induced cultures (–Dox) were considered as controls in vitro.
Data availability. The data that support the ﬁndings of this study are available
within this article and Supplementary Files, or available from the authors upon
request.
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